| | Characteristics | (%) |
| | Sex | | | Men (, %) | 28 (70.0%) | | Women (, %) | 12 (30.0%) | | Median age () | | | Symptoms | | | Abdominal pain (, %) | 34 (85.0%) | | Diarrhea (, %) | 28 (70.0%) | | Wasting (, %) | 17 (42.5%) | | Gastrointestinal bleeding (, %) | 10 (25.0%) | | Extraintestinal manifestations (, %) | 8 (20.0%) | | Comorbidities and complications | | | Fistula (, %) | 7 (17.5%) | | Stricture (, %) | 19 (47.5%) | | Anal fistula (, %) | 15 (37.5%) | | Abdominal abscess (, %) | 1 (2.5%) | | Abdominal abscess | | | L1, ileal (, %) | 4 (10.0%) | | L2, colonic (, %) | 5 (12.5%) | | L3, ileocolonic (, %) | 27 (67.5%) | | L3 + L4 ileocolonic + upper gastrointestinal (, %) | 4 (10.0%) | | Treatment | | | Mesalazine (, %) | 3 (7.5%) | | Adalimumab (, %) | 5 (12.5%) | | Ustekinumab (, %) | 4 (10.0%) | | Infliximab (, %) | 10 (25.0%) | | Vedolizumab (, %) | 4 (10.0%) | | Enteral nutrition (, %) | 11 (27.5%) | | Surgical (, %) | 1 (2.5%) |
|
|
